Minimum follow-up for inclusion was 3 months on immunosuppression therapy, and median follow-up was 17 months. Outcome measures for improvement were at least 2 lines of Snellen visual acuity (VA), expansion of the visual field isopters on kinetic perimetry (Goldmann visual fields) by at least 25%, and resolution of CME. Two patients had significant improvement in ERG amplitudes (≥50%). Medical records were reviewed for the following data: initial VA (at the start of treatment), final VA (at the last follow-up visit while on treatment), age at the onset of treatment, sex, the presence of CME, ERG amplitudes at the start of treatment (calculated as the percentage of the mean normal amplitude), the presence of negative waveforms on ERG, ARA activity on Western blot, a personal and family history of autoimmune disease (eg, systemic lupus erythematosus, asthma, Crohn disease, idiopathic thrombocytopenic purpura, multiple sclerosis, psoriasis, rheumatoid arthritis, stiff man syndrome, and thyroid disease), immunosuppressive medications used, dosage, length of treatment, and adverse effects. A digital planimeter (Lasico, Los Angeles, California) was used to measure the area in square centimeters of the visual field (isopters IV-4-e and III-4-e). The percentage change in visual field area was calculated for these isopters, and an increase in visual field size greater than 25% was considered significant. The ERG findings were expressed as a percentage of the mean normal amplitude to show the difference from reference values. The AIRs in this study include CAR, npAIR, and npAIR/CME. Although patients with MAR were evaluated during the medical record review, none were treated with immunosuppression and none were included in this study.